List of Biologics and Biosimilars
Psoriasis
TNF Blockers
Etanercept (Enbrel®, biosimilars: Erelzi™, Brenzys®)
How Does It Work?
Etanercept is a biologic that targets the overactive immune system in psoriasis. Etanercept works by supressing tumor necrosis factor-alpha (TNFa). Useful in psoriasis and psoriatic arthritis.
How Is It Used?
Etanercept is an injectable medication that is administered subcutaneously. This can be home dosed.
- For plaque psoriasis: 50 mg twice weekly for 3 months, then 50 mg once weekly thereafter
- For psoriatic arthritis: 50 mg once weekly
Side Effects?
The most common side effects of etanercept include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of etanercept, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on etanercept. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on etanercept.
Etanercept and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Etanercept should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Etanercept should be avoided in patients who are immunocompromised or HIV positive.
Interactions?
Some medications that may interact with etanercept include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with etanercept and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
- Brenzys®: https://pdf.hres.ca/dpd_pm/00065129.PDF
- Enbrel®: https://pdf.hres.ca/dpd_pm/00060454.PDF
- Erelzi™: https://pdf.hres.ca/dpd_pm/00069556.PDF
- Rymti: https://pdf.hres.ca/dpd_pm/00068678.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
Etanercept (Enbrel®): https://www.amgen.ca/products/patient-assistance/
Etanercept biosimilar (Erelzi™): Call 1-844-27XPOSE (1-844-279-7673) for information
Brenzys
Harmony patient support program
Phone 1-866-556-5663
https://rheuminfo.com/docs/physician-tools/patient-support-programs/Brenzys_EN.pdf
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| British Columbia | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Manitoba | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| New Brunswick | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| NIHB | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Northwest Territories | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Nova Scotia | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Nunavut | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Ontario | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00065129.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Quebec | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Saskatchewan | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF | |
| Yukon | Biologics and Biosimilars | Etanercept | Enbrel® | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00060454.PDF |
Adalimumab (Humira®, biosimilars: Hadlima®, Hyrimoz®, Idacio®, Amgevita®, Hulio®)
How Does It Work?
Adalimumab is a biologic that targets the overactive immune system in psoriasis. Adalimumab works by supressing tumor necrosis factor (TNFa). Useful for psoriasis and psoriatic arthritis.
How Is It Used?
Adalimumab is an injectable medication that is administered subcutaneously. This can be home dosed.
- For plaque psoriasis: 80 mg as an initial dose, then 40 mg every other week starting one week after initial dose
- For psoriatic arthritis: 40 mg every other week
- For plaque psoriasis: 50 mg twice weekly for 3 months, then 50 mg once weekly thereafter
- For psoriatic arthritis: 50 mg once weekly
Side Effects?
The most common side effects of adalimumab include temporary pain and redness around the injection site, headaches, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of adalimumab, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on adalimumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on adalimumab.
Adalimumab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Adalimumab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Interactions?
Some medications that may interact with adalimumab include abatacept (Orencia®), anakinra (Kineret®) and other TNF-blockers such as Enbrel®, Remicade®, Cimzia®, or Simponi®. Adalimumab can potentially affect the speed at which cyclosporine and warfarin are metabolized and their doses may need to be adjusted. For a complete list of medications that may interact with adalimumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
- Abrilada: https://pdf.hres.ca/dpd_pm/00068228.PDF
- Amgevita®: https://pdf.hres.ca/dpd_pm/00067468.PDF
- Hadlima®: https://pdf.hres.ca/dpd_pm/00068763.PDF
- Hulio®: https://pdf.hres.ca/dpd_pm/00071858.PDF
- Humira®: https://pdf.hres.ca/dpd_pm/00067414.PDF
- Hyrimoz®: https://pdf.hres.ca/dpd_pm/00073497.PDF
- Idacio®: https://pdf.hres.ca/dpd_pm/00058541.PDF
- Simlandi: https://pdf.hres.ca/dpd_pm/00075380.PDF
- Yuflyma: https://pdf.hres.ca/dpd_pm/00069429.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
AbbVie Care Support Program
https://abbviecare.ca/
Hadlima
Phone 1-866-556-5663 | https://harmonyorganon.ca/hadlima/en/index.html
Hyrimoz
Phone 1-888-6-SANDOZ (726369) | Email support.continum@sandoz.com
Idacio
Idacio KabiCare patient support program
https://kabicare.ca | Phone 1-888-304-2034| Email info@kabicare.ca
Amgevita
Enliven Services:
Phone: 1-877-936-2735 | Email amgevita@oneenliven.ca
www.amgevita.ca
Hulio
hulio.ca
Phone: 1-844-485-4677 | Email hulio@assistprogram.com
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| British Columbia | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Manitoba | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| New Brunswick | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| NIHB | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Northwest Territories | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Nova Scotia | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Nunavut | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Ontario | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00068228.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Quebec | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Saskatchewan | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF | |
| Yukon | Biologics and Biosimilars | Adalimumab | Humira® | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00067414.PDF |
Infliximab (Remicade®, biosimilars: Inflectra®, Renflexis®, Avsola®, Omvyence™, Remsima™)
How Does It Work?
Infliximab is a biologic that targets the overactive immune system in psoriasis. Infliximab works by supressing tumor necrosis factor-alpha (TNFa). Useful for psoriasis and psoriatic arthritis.
How Is It Used?
Infliximab is an injectable medication that is administered intravenously, useful for psoriasis and psoriatic arthritis. Typically this is done in an infusion centre.
- For plaque psoriasis: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter
- For psoriatic arthritis: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter
Side Effects?
The most common side effects of infliximab include temporary pain and redness around the infusion site, headaches, nausea, joint pain, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of infliximab, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on infliximab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on infliximab.
Infliximab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Infliximab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Interactions?
Some medications that may interact with infliximab include cyclosporine, echinacea, phenytoin, and warfarin. For a complete list of medications that may interact with infliximab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
- Avsola®: https://pdf.hres.ca/dpd_pm/00065940.PDF
- Inflectra®: https://pdf.hres.ca/dpd_pm/00057004.PDF
- Omvyence™: https://pdf.hres.ca/dpd_pm/00068865.PDF
- Remicade®: https://pdf.hres.ca/dpd_pm/00075118.PDF
- Remsima™: https://pdf.hres.ca/dpd_pm/00074581.PDF
- Renflexis®: https://pdf.hres.ca/dpd_pm/00072737.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
Infliximab (Remicade®): https://www.bioadvancemember.ca/en/global/home
Infliximab biosimilar Inflectra®: https://www.pfizer.ca/assistance-programs
Infliximab biosimilar Renflexis®: http://www.merckharmony.ca/
Avsola
Enliven Services
Ph: 1-877-9ENBREL (936-2735) | Email info@oneenliven.ca
www.enbrel.ca; www.avsola.ca
Remsima
CELLTRION CONNECT™ patient support program for Remsima
Interested individuals can find out more about CELLTRION CONNECT™ by visiting www.celltrionconnect.ca/
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| British Columbia | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Manitoba | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| New Brunswick | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| NIHB | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Northwest Territories | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Nova Scotia | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Nunavut | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Ontario | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00065940.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Quebec | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Saskatchewan | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF | |
| Yukon | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00075118.PDF |
Golimumab (Simponi®)
How Does It Work?
Golimumab is a biologic that targets the overactive immune system in psoriatic arthritis. Golimumab works by supressing tumor necrosis factor-alpha (TNFa).
How Is It Used?
Golimumab is a biologic medication that can be administered either subcutaneously or intravenously.
Side Effects?
The most common side effects of golimumab are an increased risk of infection and a temporary injection site reaction. To obtain a comprehensive list of all known potential side effects of golimumab, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on golimumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on golimumab.
Golimumab should be avoided in patients with severe heart failure.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Interactions?
Some medications that may interact with golimumab include abatacept, anakinra, baricitinib, belimumab, canakizumab, certolizumab pegol, cladribine, echinacea, infliximab, leflunomide, natalizumab, pimecrolimus, rilonacept, roflumilast, tacrolimus, tocilizumab, tofacitinib, and vedolizumab. For a complete list of medications that may interact with golimumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Golimumab | Simponi® | SA | SA | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| British Columbia | Biologics and Biosimilars | Golimumab | Simponi® | SA | SA | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Manitoba | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – EDS | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| New Brunswick | Biologics and Biosimilars | Golimumab | Simponi® | SA | SA | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Golimumab | Simponi® | N/A | SA | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| NIHB | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – L/U | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Northwest Territories | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – L/U | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Nova Scotia | Biologics and Biosimilars | Golimumab | Simponi® | SA | SA | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Nunavut | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – L/U | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Ontario | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes - EAP | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Golimumab | Simponi® | No | Yes – S/A | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Quebec | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Saskatchewan | Biologics and Biosimilars | Golimumab | Simponi® | No | Yes – EDS | https://pdf.hres.ca/dpd_pm/00074084.PDF | |
| Yukon | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – EDS | https://pdf.hres.ca/dpd_pm/00074084.PDF |
Certolizumab pegol (Cimzia®)
How Does It Work?
Certolizumab is a biologic that targets the overactive immune system in psoriasis. Certolizumab works by supressing tumor necrosis factor-alpha (TNFa).
Useful in psoriasis and psoriatic arthritis.
How Is It Used?
Certolizumab is an injectable medication that is administered subcutaneously.
- For plaque psoriasis: 400 mg every 2 weeks
- For psoriatic arthritis: 400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks
Side Effects?
The most common side effects of certolizumab include joint pain, and an increased risk of upper respiratory tract infections and urinary tract infections. To obtain a comprehensive list of all known potential side effects of certolizumab, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on certolizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on certolizumab.
Certolizumab should be avoided in patients with moderate to severe heart failure.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Interactions?
Some medications that may interact with certolizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with certolizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
UCB Cares 1-800-908-5555
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | SA | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| British Columbia | Biologics and Biosimilars | Certolizumab-pergol | Cimzia® | No | SA | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Manitoba | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EDS | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| New Brunswick | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | SA | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| NIHB | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – L/U | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Northwest Territories | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – L/U | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Nova Scotia | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | SA | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Nunavut | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – L/U | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Ontario | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EAP | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Quebec | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A | https://pdf.hres.ca/dpd_pm/00053920.PDF | |
| Saskatchewan | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | https://pdf.hres.ca/dpd_pm/00053920.PDF | |||
| Yukon | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EDS | https://pdf.hres.ca/dpd_pm/00053920.PDF |
IL17 Blockers
Ixekizumab (Taltz®)
How Does It Work?
Ixekizumab is a biologic that targets the overactive immune system in psoriasis. Ixekizumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis.
How Is It Used?
Ixekizumab is an injectable medication that is administered subcutaneously.
- For plaque psoriasis: 160 mg once, followed by 80 mg at weeks 2, 4, 6, 8, 10 and 12, and then 80 mg every 4 weeks
- For psoriatic arthritis: 160 mg once, followed by 80 mg every 4 weeks
Side Effects?
The most common side effects of ixekizumab include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ixekizumab, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on ixekizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ixekizumab.
Ixekizumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Interactions?
Some medications that may interact with ixekizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ixekizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
Call 1-877-219-8908 for information.
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| British Columbia | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Manitoba | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| New Brunswick | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| NIHB | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Northwest Territories | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Nova Scotia | Biologics and Biosimilars | Ixekizumab | Taltz | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Nunavut | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Ontario | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | No | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Quebec | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Saskatchewan | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF | |
| Yukon | Biologics and Biosimilars | Ixekizumab | Taltz® | SA | SA | https://pdf.hres.ca/dpd_pm/00069828.PDF |
Secukinumab (Cosentyx®)
How Does It Work?
Secukinumab is a biologic that targets the overactive immune system in psoriasis. Secukinumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis.
How Is It Used?
Secukinumab is an injectable medication that is administered subcutaneously.
- For plaque psoriasis: 300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks
- For psoriatic arthritis: For patients not treated previously by a biological agent – 150 mg (or 300 mg for some patients) once weekly at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks. For those with previous treatment with a biologic agent – 300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.
Side Effects?
The most common side effect of secukinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of secukinumab, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on secukinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on secukinumab.
Secukinumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Interactions?
Some medications that may interact with secukinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with secukinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
https://www.cosentyx.ca/home/plaque-psoriasis/xpose-your-support-network/
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| British Columbia | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Manitoba | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| New Brunswick | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| NIHB | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Northwest Territories | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Nova Scotia | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Nunavut | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Ontario | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | No | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Quebec | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Saskatchewan | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF | |
| Yukon | Biologics and Biosimilars | Secukinumab | Cosentyx® | SA | SA | https://pdf.hres.ca/dpd_pm/00075631.PDF |
IL12/23 Blockers
Ustekinumab (Stelara®)
How Does It Work?
Ustekinumab is a biologic that targets the overactive immune system in psoriasis. Ustekinumab works by suppressing interleukin 12 and interleukin 23. Useful for psoriasis and psoriatic arthritis.
How Is It Used?
Ustekinumab is an injectable medication that is administered subcutaneously. Can be home dosed.
- For plaque psoriasis:
≤100 kg: 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter
>100 kg: 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter - For psoriatic arthritis: 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter.
Side Effects?
The most common side effect of ustekinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ustekinumab, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on ustekinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ustekinumab.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment
Interactions?
Some medications that may interact with ustekinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ustekinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
- Jamteki: https://pdf.hres.ca/dpd_pm/00073286.PDF
- Stelara®: https://pdf.hres.ca/dpd_pm/00073994.PDF
- Wezlana: https://pdf.hres.ca/dpd_pm/00073953.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| British Columbia | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Manitoba | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| New Brunswick | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| NIHB | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Northwest Territories | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Nova Scotia | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Nunavut | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Ontario | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Quebec | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Saskatchewan | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF | |
| Yukon | Biologics and Biosimilars | Ustekinumab | Stelara® | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | SA - biosimilars A limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions | https://pdf.hres.ca/dpd_pm/00073994.PDF |
Guselkumab (TREMFYA®)
How Does It Work?
Guselkumab is a biologic that targets the overactive immune system in psoriasis. Guselkumab works by neutralizing interleukin-23.
How Is It Used?
Guselkumab is an injectable medication that is administered subcutaneously by injection. Guselkumab can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) such as methotrexate.
- For plaque psoriasis: 100 mg at weeks 0 and 4, and then every 8 weeks thereafter
- For psoriatic arthritis: 100 mg at weeks 0 and 4, and then every 8 weeks thereafter
Side Effects?
The most common side effect of guselkumab is an increased risk of respiratory tract infections. To obtain a comprehensive list of all known potential side effects of guselkumab, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on guselkumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on guselkumab.
Patients should be screened for tuberculosis and infections prior to treatment.
Do not use TREMFYA®/TREMFYA One-Press™ if you are allergic to guselkumab or any of the ingredients in TREMFYA®/TREMFYA OnePress™.
If you think you are allergic, ask your healthcare professional for advice before using TREMFYA®/TREMFYA One-Press™.
Interactions?
For a complete list of medications that may interact with guselkumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes – EDS | Yes – EDS | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| British Columbia | Biologics and Biosimilars | guselkumab | Tremfya® | Yes – EDS | Yes – EDS | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Manitoba | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - EDS | Yes - EDS | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| New Brunswick | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes – S/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Guselkumab | Tremfya® | SA | SA | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| NIHB | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - L/U | Yes - L/U | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Northwest Territories | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - L/U | Yes - L/U | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Nova Scotia | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes – EDS | Yes – EDS | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Nunavut | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - L/U | Yes - L/U | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Ontario | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - L/U | Yes - EAP | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes – S/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Quebec | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - S/A | No | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Saskatchewan | Biologics and Biosimilars | Guselkumab | Tremfya® | Yes - EDS | Yes - EDS | https://pdf.hres.ca/dpd_pm/00075605.PDF | |
| Yukon | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | https://pdf.hres.ca/dpd_pm/00075605.PDF |
Abatacept
Abatacept (Orencia®)
How Does It Work?
Abatacept is a biologic that targets the overactive immune system in psoriatic arthritis. Abatacept works by supressing the activation of white blood cells called T-cells.
How Is It Used?
Abatacept is a biologic medication that can be administered either subcutaneously or intravenously.
Side Effects?
The most common side effects of abatacept are headache, nausea, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of abatacept, talk your doctor or pharmacist.
Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on abatacept. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on abatacept.
Patients with chronic obstructive pulmonary disease (COPD) are at an increased risk of experience COPD-related adverse events such as cough, shortness of breath, and infection while on abatacept.
Abatacept should be avoided in patients who are immunocompromised or HIV positive.
Interactions?
Some medications that may interact with abatacept include anakinra, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, baricitinib, belimumab, cladribine, echinacea, leflunomide, natalizumab, pimecrolimus, rituximab, roflumilast, tacrolimus, tocilizumab, and tofacitinib. For a complete list of medications that may interact with abatacept and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
N/A
| Province | Class | Generic name | Drug Name | Psoriasis | Psoriatic arthritis | GPP | monograph |
|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| British Columbia | Systemic Drugs | Abatacept | Orencia | N/A | No | ||
| Manitoba | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| New Brunswick | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Newfoundland and Labrador | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| NIHB | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Northwest Territories | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Nova Scotia | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Nunavut | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Ontario | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Prince Edward Island | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Quebec | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Saskatchewan | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF | |
| Yukon | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00070861.PDF |